| 词条 | Exisulind |
| 释义 |
| ImageFile = Exisulind structure.svg | ImageSize = 225px | ImageAlt = | IUPACName = 2-[(1Z)-5-fluoro-1-[(4-methanesulfonylphenyl)methylidene]-2-methyl-1H-inden-3-yl]acetic acid | OtherNames = Sulindac sulfone, Aptosyn, FGN-1, Prevatac |Section1={{Chembox Identifiers | CASNo = 59973-80-7 | PubChem = 5472495 | ChemSpiderID = 4582441 | InChI = 1/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9- | InChIKey = MVGSNCBCUWPVDA-MFOYZWKCBW | StdInChI = 1S/C20H17FO4S/c1-12-17(9-13-3-6-15(7-4-13)26(2,24)25)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9- | StdInChIKey = MVGSNCBCUWPVDA-MFOYZWKCSA-N | RTECS = | MeSHName = | ChEBI = 64212 | ChEMBL = 488025 | SMILES = CC1=C(CC(O)=O)C2=C(C=CC(F)=C2)\\C1=C/C1=CC=C(C=C1)S(C)(=O)=O }} |Section2={{Chembox Properties | Formula = | MolarMass = 372.41 g/mol | Appearance = | Density = | MeltingPt = | BoilingPt = | Solubility = }} |Section3={{Chembox Hazards | MainHazards = | FlashPt = | AutoignitionPt = }} }}Exisulind (tentative trade name Aptosyn) is an antineoplastic agent. It acts by inhibiting the enzyme cyclic guanosine monophosphate phosphodiesterase type 5 ({{EC number|3.1.4.17}}).[1] It is the sulfone derivative of sulindac, an NSAID. Unlike sulindac, it has known effects on prostaglandin synthesis.[2] It was developed as the potential treatment of several conditions including familial adenomatous polyposis (FAP), precancerous sporadic colonic polyps, cervical dysplasia and the prevention of tumor recurrence in prostate and breast cancer.[3] Exisulind inhibits the enzyme cGMP-PDE, overexpressed in precancerous and cancerous colorectal cells, and induces apoptosis in such cells with minimal effects on normal cells. This apoptotic effect is independent of COX-1 or COX-2 inhibition, p53, Bcl-2, or cell cycle arrest. Preclinical evidence suggests that exisulind also inhibits angiogenesis.[4] See also
References1. ^{{cite journal|last1=[No authors listed]|title=Exisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfone.|journal=Drugs in R&D|date=2004|volume=5|issue=4|pages=220–6|pmid=15230629}} {{Antineoplastic-drug-stub}}2. ^{{cite journal|last1=van Stolk|first1=R|last2=Stoner|first2=G|last3=Hayton|first3=WL|last4=Chan|first4=K|last5=DeYoung|first5=B|last6=Kresty|first6=L|last7=Kemmenoe|first7=BH|last8=Elson|first8=P|last9=Rybicki|first9=L|last10=Church|first10=J|last11=Provencher|first11=K|last12=McLain|first12=D|last13=Hawk|first13=E|last14=Fryer|first14=B|last15=Kelloff|first15=G|last16=Ganapathi|first16=R|last17=Budd|first17=GT|title=Phase I trial of Exisulind (Sulindac Sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis.|journal=Clinical Cancer Research|date=January 2000|volume=6|issue=1|pages=78–89|pmid=10656435}} 3. ^{{cite journal|last1=Griffiths|first1=GJ|title=Exisulind Cell Pathways.|journal=Current Opinion in Investigational Drugs|date=November 2000|volume=1|issue=3|pages=386–91|pmid=11249724}} 4. ^{{cite journal|last1=Skopińska-Rózewska|first1=E|last2=Piazza|first2=GA|last3=Sommer|first3=E|last4=Pamukcu|first4=R|last5=Barcz|first5=E|last6=Filewska|first6=M|last7=Kupis|first7=W|last8=Caban|first8=R|last9=Rudziński|first9=P|last10=Bogdan|first10=J|last11=Mlekodaj|first11=S|last12=Sikorska|first12=E|title=Inhibition of Angiogenesis by Sulindac and its Sulfone Metabolite (FGN-1): a Potential Mechanism for Their Antineoplastic Properties.|journal=International Journal of Tissue Reactions|date=1998|volume=20|issue=3|pages=85–9|pmid=9894180}} 4 : Antineoplastic drugs|Sulfones|Carboxylic acids|Indenes |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。